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Abstract
Background: Soluble endoglin, a TGF-b receptor, plays a key role in cardiovascular physiology. Whether circulating
concentrations of soluble endoglin are elevated in CKD or underlie the high risk of cardiovascular death associated with
chronic kidney disease (CKD) is unknown.
Methods: Individuals with and without CKD were recruited at a single center. Estimated glomerular filtration rate (eGFR) was
estimated using the modified MDRD study equation and the serum creatinine at the time of recruitment, and patients were
assigned to specific CKD stage according to usual guidelines. Serum endoglin concentration was measured by ELISA and
univariate and multivariable regression was used to analyze the association between eGFR or CKD stage and the
concentration of soluble endoglin.
Results: Serum endoglin was measured in 216 patients including 118 with stage 3 or higher CKD and 9 individuals with end
stage renal disease (ESRD). Serum endoglin concentration did not vary significantly with CKD stage (increase of 0.16 ng/mL
per 1 stage increase in CKD, P=0.09) or eGFR (decrease -0.06 ng/mL per 10 mL/min/1.73 m
2 increase in GFR, P=0.12), and
was not higher in individuals with ESRD than in individuals with preserved renal function (4.261.1 and 4.361.2 ng/mL,
respectively). Endoglin concentration was also not significantly associated with urinary albumin excretion.
Conclusions: Renal function is not associated with the circulating concentration of soluble endoglin. Elevations in soluble
endoglin concentration are unlikely to contribute to the progression of CKD or the predisposition of individuals with CKD to
develop cardiovascular disease.
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Introduction
Angiogenesis plays a critical role in renal homeostasis, and
emerging data have increasingly suggested that dysregulation of
angiogenesis contributes to the progression of chronic kidney
disease (CKD) and its associated complications[1,2,3,4,5,6,7,8,9].
Increases in the circulating levels of angiogenesis inhibitors may
play an important role in the rarefaction of renal capillaries that
accompanies uremia[8]. Similarly, a wealth of data has demon-
strated that vascular endothelial growth factor (VEGF) signaling
plays a critical role in the maintenance of normal glomerular
function[1,5,7,10], and that inhibiting VEGF induces hyperten-
sion, proteinuria and significant pathologic changes within the
glomerulus [6,7,10,11].
The auto-regulation of angiogenesis plays a similarly important
role in cardiovascular homeostasis [12,13,14]. Inhibition of VEGF
signaling, for example, induces interstitial inflammation and
endothelial apoptosis in the heart [15,16], and in both animal
models and human CKD uremia is accompanied by significant
rarefaction of the myocardial microvasculature[12,13,17]. These
observations suggest that circulating anti-angiogenic factors may
contribute to the progression of CKD and that their concentrations
are likely to be elevated in individuals with significant loss of
glomerular filtration rate (GFR) or proteinuria. Furthermore,
Elevations in the ambient level of circulating angiogenesis inhibitors
in individuals with CKD would also provide a mechanistic
explanation for the high risk of cardiovascular morbidity and
mortality associated with CKD.
Although, two recent studies have demonstrated that soluble fms-
like kinase (sFLT-1) concentration rises as GFR declines [18,19], it
remains uncertain whether angiogenesis inhibitors are generally
elevated in the setting of CKD or whether sFLT-1 is uniquely
increased in this respect. In particular, it is unknown whether the
concentration of soluble endoglin, a key angiogenesis inhibitor
implicated in the pathogenesis of preeclampsia cardiovascular
disease, hypertension and endothelial dysfunction [20,21,22,23], is
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the pathogenesis of renal and cardiovascular pathology, we
hypothesized that elevations in the concentration of circulating
endoglin in CKD could contribute to the progression of CKD and
underlie the association of CKD and cardiovascular disease. We
undertook this study in order to determine whether endoglin levels
are higher in individuals with CKD compared to individuals with
preserved renal function.
Methods
Ethics Statement
This research was approved by and conducted in accordance
with the standards of the local institutional review committees of
the Brigham & Women’s Hospital and Beth Israel Deaconess
Medical Center and the principles of the Declaration of Helsinki.
All subjects involved in the research signed written informed
consent forms prior to enrollment.
Subjects
Subjects with and without CKD between the ages of 18–80 years
old were recruited from the cardiac catheterization lab and the
outpatient nephrology clinics (including the general nephrology,
stone, and renal transplant donor clinics) of Brigham and Women’s
Hospital. Individuals receiving anti-angiogenic or immunosuppres-
sive therapy, those with active malignancy or acute coronary
ischemia, a history of thoracic or abdominal radiation therapy, and
individuals with acute kidney injury were excluded. Individuals
undergoing angiography were additionally excluded if they had a
history of prior coronary artery bypass surgery.
Clinical Data and Laboratories
Data on blood pressure, demographics and baseline clinical
conditions were obtained by patient interview, supplemental chart
review and a brief exam at the time of recruitment. Serum
creatinine, albumin, and hemoglobin were measured on the day of
enrollment in the hospital laboratory using standard clinical
techniques. The most recent measurements of total cholesterol,
urinary albumin and creatinine excretion within 6 months of
recruitment were also collected. Estimated glomerular filtration rate
(eGFR) was calculated using the modified MDRD equation [24].
Renal function was categorized using a modification of the National
Kidney Foundation 5-stage system [25]. Because the MDRD
equation is not precise in patients with preserved renal function,
individuals with eGFR $90 mL/min/1.73 m
2 were combined into
a single category (‘‘preserved function/stage 1 CKD)—this category
included all patient with eGFR$90 mL/min/1.73 m
2.A sa
sensitivity analysis, we separately analyzed endoglin concentrations
in those whose GFR was estimated to be within the normal range
(eGFR $110 mL/min/1.73 m
2) [26] and in individuals who were
seen as transplant donors or for renal stones (without concomitant
CKD). Non-dialysis dependent stage 4 and 5 CKD were considered
jointly, chronic dialysis patients were evaluated as a unique category.
Samples and Measurement of Endoglin
Serum was centrifuged within 15 minutes at 1000 g and stored
at 280uC. Samples were batch analyzed for soluble endoglin
concentration in a blinded fashion using ELISA kits from R&D
systems. Intra and inter-assay coefficient of variations for the assay
were 4.0 and 13.1%, respectively.
Statistical Analysis
Data are presented as mean6standard deviation (SD), n (%) or
median (inter-quartile ratio, IQR). Differences in baseline
characteristics such as demographic data, blood pressure and
comorbid medical conditions across categories of renal function
were compared using ANOVA or non-parametric trend tests for
continuous data and Chi-Square tests of trend for count data. The
Pearson correlation coefficient was used to measure correlation
between continuous variables. The relationship between eGFR or
categories of renal function and soluble endoglin was assessed
using univariate linear regression and a series of 4 different
multivariable regression models to correct for potential confound-
ing. The primary comparison was performed using linear
regression models with serum endoglin concentration as the
dependent variable, renal function (either as a continuous or
categorical variable) as the primary independent variable and with
additional adjustment for age, sex, race, diabetes, hypertension,
smoking, cholesterol, congestive heart failure, peripheral vascular
disease, and obstructive lung disease and recruitment site (Model
1). An expanded linear regression model (Model 2) additionally
adjusted for Hispanic ethnicity and serum albumin. Additional
linear models including terms for interaction with diabetes and
recruitment site (outpatient clinics vs. coronary catheterization lab)
were performed as a pre-specified analysis. Two sensitivity
analyses were performed in order to examine the robustness of
our results and their sensitivity to modeling assumptions. In the
first, the independent terms from Model 1 were used in an ordered
categorical regression model using quartiles of endoglin as the
outcome variable. Logistic regression models using the median
value of endoglin as the cutoff were generated in an analogous
fashion. Model fit was tested using graphical techniques,
inspection of residual distribution, and tests of model specification.
All analyses were performed in STATA 9.0 (Stata Corporation,
College Station, TX). P,0.05 was considered significant for all
analyses.
Results
Baseline Characteristics
As shown in Table 1 and Table 2, serum creatinine and eGFR
weresignificantlydifferentacrosscategoriesofrenalfunction:eGFR
in preserved function/Stage 1 CKD 105.9612.0 mg/dL, Stage 2
CKD 73.868.5, Stage 3 CKD 44.868.5, Stage 4/5 CKD
22.566.5, Dialysis , 8.962.1 ,P ,0.001. Age increased across
increasing categories of CKD, but was actually lower in individuals
on dialysis (52.3618.0 years) than in individuals with preserved
renal function/stage 1 CKD (57.368.0). Among baseline comor-
bidities,onlycoronaryarterydisease(P=0.003),peripheralvascular
disease (P=0.007), and diabetes (P=0.01) demonstrated a
significantly increasing frequency across categories of renal
function. Congestive heart failure was more prevalent in individuals
with more severe renal dysfunction, but this trend did not achieve
significance (P=0.07). Diastolic blood pressure increased from
74.0612.9 in individuals with preserved function/Stage 1 CKD to
82.6618.5 in individuals on dialysis (P=0.02). Similar trends were
observed with systolic blood pressure but were not significant.
Urinary albumin excretion was available for 66 patients.
Logarithmically transformed albumin to creatinine ratio was
5.06 mg/G among those with preserved renal function, 4.062.3
in those with stage 2 CKD, and 4.162.0 mg/G in those with stage
3 CKD, and 5.161.5 in those with stage 4/5 CKD (P=0.51).
Endoglin Concentration and Renal Function
Endoglin concentration did not vary significantly across
categories of baseline renal function (Figure 1). Mean Endoglin
concentration was 4.361.2 ng/mL among those with preserved
renal function, 4.561.7 ng/mL in stage 2 CKD, 4.761.6 ng/mL
Endoglin in CKD
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4.261.1 ng/mL in individuals with ESRD, (P=0.12). There was
a non-significant (P=0.09) trend consistent with an increase in
endoglin across categories of CKD among the subgroup of
subjects not on chronic dialysis. However, as shown in Figure 2,
the correlation was weak (r=0.12) and non-significant (P=0.05).
Within the preserved renal function/stage 1 CKD group, endoglin
concentrations were not different in individuals with eGFR
$110 mL/min/1.73 m
2 compared with eGFR 90-,110 mL/
min (4.6561.32 ng/mL vs. 4.0961.09 ng/mL, P=0.23). Endo-
glin concentration was also similar among individuals recruited as
transplant donors/stone patients compared to subjects with
eGFR$90 recruited for other reasons (4.2460.74 ng/mL vs.
4.2761.21, P=0.95). Endoglin concentration also did not vary
across categories of renal function when eGFR.110 mL/min/
1.73 m
2 (P=0.16) or transplant donor/stone patient (P=0.19)
were considered as distinct categories of baseline renal function.
Although endoglin concentrations were marginally higher
among individuals recruited from clinic (b=0.67, P=0.003,
Table 3) than in individuals recruited from the catheterization
lab, the association between endoglin concentration and class of
renal function was qualitatively similar in both groups, and it was
not significantly associated with CKD class, P=0.45 and P=0.43,
respectively (Table 4). The association between endoglin and
CKD was also non-significant when the analysis was restricted to
women (P=0.21) or to the subgroup of individuals with diabetes
(P=0.28). Among other baseline and demographic characteristics,
only the presence of diabetes (b=0.47, P=0.04) was significantly
associated with circulating endoglin concentration. Neither total
cholesterol nor baseline hemoglobin concentration was associated
with circulating endoglin concentration. Although endoglin
concentrations were lower in individuals with serum albumin
concentrations less than the median value of #4.3 gm/dL
compared with individuals with albumin . 4.3 gm/dL
(4.461.5 ng/mL vs. 4.962.0 ng/mL), the difference was not
significant, P=0.07.
To understand whether the apparent lack of an association
between renal function and endoglin concentration was con-
founded by other characteristics, we constructed a series of
multivariable regression models as shown in Tables 5 and 6.
Adjusting for age, sex, race, diabetes, hypertension, smoking,
cholesterol, congestive heart failure, peripheral vascular disease,
obstructive lung disease, and recruitment site attenuated the
association between baseline renal function and circulating
Table 1. Baseline Clinical Characteristics of the Study Population.
Characteristic
Preserved
Function-Stage
1 CKD Stage 2 CKD Stage 3 CKD Stage 4-5 CKD Dialysis P Value
*
(Mean±S.D.) (N=30) (N=5) (N=92) (N=27) (N=9)
Demographics
Age, years 57.3 68.0 59.8 611.3 63.5613.2 68.2614.7 52.3618.0 0.001
Male, n (%) 22 (73.3) 38 (65.5) 49 (53.3) 18 (66.7) 3 (33.3) 0.10
Race, n (%)
Black 3 (10.0) 9 (15.8) 10 (11.2) 4 (15.4) 4 (44.4) 0.06
White 25 (83.3) 42 (73.7) 68 (76.4) 18 (69.2) 2 (22.2)
Other 2 (6.7) 6 (10.5) 11 (12.4) 4 (15.4) 3 (33.3)
Hispanic 2 (6.7) 6 (10.3) 15 (16.5) 6 (24.0) 2 (22.2) 0.31
Physical Exam
Weight, kilogram 86.1619.2 86.8 621.7 89.8623.8 85.5620.0 81.9632.7 0.87
Systolic blood pressure, mm Hg 128.0624.2 124.7617.3 128.9621.4 130.2619.7 146.4613.8 0.08
Diastolic blood pressure, mm Hg 74.0612.9 70.7611.2 67.8611.9 70.8620.9 82.6618.5 0.02
Past Medical History, n( % )
Coronary disease 13 (76.5) 17 (43.6) 20 (26.0) 10 (38.5) 3 (42.9) 0.003
Hypertension 23 (76.7) 42 (72.4) 72 (78.3) 25 (92.6) 9 (100.0) 0.13
Diabetes 9 (30.0) 20 (34.5) 45 (48.9) 19 (70.4) 5 (55.6) 0.01
Congestive heart failure 4 (13.3) 11 (19.0) 16 (17.4) 6 (22.2) 5 (55.6) 0.07
Obstructive lung disease 0 (0.0) 2 (3.5) 6 (6.5) 1 (3.7) 2 (22.2) 0.10
Peripheral vascular disease 2 (6.7) 3 (5.2) 8 (8.7) 8 (29.6) 2 (22.2) 0.007
Hyperlipidemia 21 (70..0) 42 (72.4) 62 (67.4) 19 (70.4) 6 (66.7) 0.98
Smoking 3 (13.0) 9 (17.0) 7 (8.1) 0 (0.0) 1 (12.5) 0.17
Cause of CKD 0.29
Diabetes -- -- 13 (14.1) 8 (29.6) 1 (11.1)
Hypertension -- -- 17 (18.5) 2 (7.4) 2 (22.2)
Other/Unknown -- -- 62 (67.4) 17 (63.0) 6 (66.7)
S.D.=Standard deviation., I.Q.R.=Interquartile Range,
*ANOVA for normally distributed continuous variables, chi-square test for -parametric trend test for non-normally distributed continuous variables, and chi-squared
tests for count variables.
doi:10.1371/journal.pone.0023718.t001
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function and endoglin concentration were observed regardless of
whether renal function was analyzed as a continuous (eGFR) or
categorical (CKD class) predictor. Results were qualitatively
similar after additional adjustment for Hispanic ethnicity and
serum albumin concentration, and the association between renal
function and endoglin concentration remained non-significant
(P$0.42) regardless of whether endoglin concentration was
analyzed as a continuous or categorical outcome variable. There
was no evidence for a significant interaction between renal
function and diabetes or renal function and recruitment site in any
of the models (Linear Model Pinteraction=0.53 and 0.17 for
interactions between eGFR and diabetes and GFR and recruit-
ment site, respectively).
Table 2. Baseline Laboratory Characteristics of the Study Population.
Characteristic
Preserved
Function-Stage
1 CKD Stage 2 CKD Stage 3 CKD Stage 4-5 CKD Dialysis P Value
*
(Mean±S.D.) (N=30) (N=5) (N=92) (N=27) (N=9)
Labs
Total cholesterol, mg/dL 160.6 632.9 160.4642.9 166.6641.6 147.2640.6 147.4642.9 0.42
Hemoglobin, g/dL 13.961.4 13.262.0 12.961.8 12.061.5 11.861.8 ,0.001
Creatinine, mg/dL 0.860.1 1.060.2 1.660.4 3.362.0 7.163.4 ,0.001
Blood urea nitrogen, mg/dL 14.563.8 20.265.8 30.3610.7 55.6628.5 42.1612.9 ,0.001
Estimated GFR, mL/min/1.73 m
2 105.9612.0 73.868.5 44.868.5 22.266.5 8.962.9 ,0.001
Albumin, gm/dL 4.160.4 4.260.3 4.360.4 4.160.4 3.660.5 ,0.001
Albumin:creatinine ratio, mg/G, 0.0 (152.3) 20.7 (433.0) 53.8 (216) 90.4 (184.1) 0.37
median (IQR)
1
Log albumin:creatinine, mg/G
1 5.0 4.062.3 4.162.0 5.161.5 0.51
S.D.=Standard deviation., I.Q.R.=Interquartile Range,
*ANOVA for normally distributed continuous variables, chi-square test for -parametric trend test for non-normally distributed continuous variables, and chi-squared
tests for count variables.
1N=66: Preserved renal function n=1, Stage 2 CKD n=10, Stage 3 CKD n=44, Stage 4/5 CKD n=11.
doi:10.1371/journal.pone.0023718.t002
Figure 1. Endoglin concentration according to CKD class. Number of patients for each category is listed within the corresponding bar.
doi:10.1371/journal.pone.0023718.g001
Endoglin in CKD
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restricted cubic spline, and were not suggestive of an association
between renal function and endoglin concentration (Figure S1).
Endoglin Concentration and Albuminuria
Urinary albumin concentrations were higher among individuals
with higher circulating endoglin concentrations (Figure 3).
However, this correlation was weak and did not achieve statistical
significance (r=0.13, P=0.30).
Discussion
Changes in the regulation of angiogenesis appears to be a key
factor in the pathogenesis of CKD and cardiovascular disease
[1,2,3,4,5,6,7,27,28]. This suggests that increased concentrations
of angiogenesis inhibitors may partly explain the markedly
increased risk of developing and dying from cardiovascular disease
in individuals with CKD. Endoglin, an ancillary TGF-b receptor,
is a key player in angiogenesis, nitric oxide coupling and heart
development that plays an important regulatory role in both renal
and cardiovascular disease [20,29,30,31]. We therefore hypothe-
sized that an increase in soluble endoglin concentration as GFR
declines might contribute to the progression of CKD or play a
mechanistic role in the association of CKD with increased risks of
developing and dying from cardiovascular disease.
In this study, we analyzed 216 individuals with various degrees
of renal dysfunction and were unable to confirm an association
between CKD and increases in the concentration of soluble
endoglin. We found, in fact, that patients with ESRD, the most
severe form of renal dysfunction, had on average the lowest
circulating concentration of soluble of endoglin. Renal protein
excretion, another indicator of renal disease, was also not
associated with circulating endoglin concentration in the subset
of patients in whom albuminuria was measured. Our data thus
suggest that an elevation in the baseline concentration of soluble
endoglin with progressive CKD is unlikely to play a causative role
in the progression of CKD or the association of CKD with
cardiovascular disease. They further suggest that, despite its well
described role in the pathogenesis of preeclampsia [20], elevation
in the baseline concentration of soluble endoglin is unlikely to
underlie the increased risk of preeclampsia associated with CKD.
Experimental studies have consistently demonstrated that both
glomerular and renal interstitial endoglin expression increase
dramatically following induction of either acute or chronic renal
dysfunction, regardless of the mechanism of renal injury
[32,33,34,35]. Similarly, a single human study demonstrated
Figure 2. Scatter plots of endoglin concentration vs. estimated glomerular filtration rate. a) All comers b) Dialysis patients excluded c)
Patients recruited in clinic.
doi:10.1371/journal.pone.0023718.g002
Table 3. Univariate Associations of Clinical Characteristics
with Endoglin Concentration.
Characteristic
Unadjusted
B (95% CI) P Value
Demographics
Age
#40 years Reference Reference
40-60 years -0.15 0.76
.60 years -0.47 0.32
Male, n (%) 0.27 0.25
Black Race (vs. other race) 0.48 0.15
Hispanic -0.41 0.21
Recruitment site, (clinic vs. 0.67 0.003
cardiac catheterization lab)
Physical Exam
Weight, kilogram, .88.6 vs. #88.6 Kg 0.31 0.31
Systolic blood pressure, per 10 mm Hg 0.01 0.37
Diastolic blood pressure, per quintile 0.12 0.15
Past Medical History
Coronary disease -0.11 0.71
Hypertension 0.13 0.64
Diabetes 0.47 0.04
Congestive heart failure 0.16 0.58
Obstructive lung disease -0.15 0.78
Peripheral vascular disease 0.25 0.50
Hyperlipidemia -0.12 0.64
Smoking 0.10 0.80
Cause of CKD
Diabetes 1.35 0.001
Hypertension 1.27 0.002
Other/Unknown Reference Reference
Labs
Total cholesterol, . 158 vs. #158 mg/dL -0.27 0.37
Hemoglobin, .13 vs. #13 g/dL 0.29 0.23
Albumin, .4.3 vs. #4.3 g/dL 0.50 0.07
mg=milligram. G=gram. dL=deciliter. Kg=kilogram. CKD=Chronic Kidney
Disease.
doi:10.1371/journal.pone.0023718.t003
Table 4. Univariate Associations of Renal Function with
Endoglin Concentration.
Characteristic Unadjusted B P Value
(95% CI)
Renal Function
Estimated GFR (per
10/mL/min/1.73m
2)
-0.06 0.12
CKD Class (per 1
category change)
*
0.16 0.09
CKD Category -- --
Preserved Renal
function/Stage 1 CKD
Reference Reference
Stage 2 CKD 0.18 (-0.56, 0.92) 0.63
Stage 3 CKD 0.46 (-0.23, 1.15) 0.19
Stage 4-5 CKD 1.03 (0.15, 1.90) 0.02
Dialysis -0.10 0.89
GFR=glomerular filtration rate CKD Classes include normal/stage 1 CKD, stage
2 CKD, stage 3 CKD, stage 4/5 CKD, and dialysis.
doi:10.1371/journal.pone.0023718.t004
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diseased compared with healthy human kidneys [36]. The absence
of an increase in soluble endoglin in our study suggests that the
increases in tissue concentrations of endoglin following renal injury
are not accompanied by concomitant release of cellular endoglin
into the circulation.
To the best of our knowledge, ours is the first study to analyze
the association of circulating endoglin concentration with renal
function. The apparent lack of an association between either GFR
or proteinuria and circulating endoglin concentration is surprising.
Although our study was not designed to explore the mechanisms
controlling the synthesis of endoglin, a low rate of release of
membrane bound endoglin into the circulation as well as a
differential regulation of the production of the soluble and
membrane forms of endoglin may explain these contrasting
findings.
Our findings are also notable in light of recent studies
demonstrating an inverse correlation between eGFR and sFLT-1
and a direct correlation between sFLT-1 and proteinuria [18,37].
These findings suggested the possibility that a universal,
Table 5. Adjusted Association of Glomerular Filtration Rate
with Endoglin Concentration.
Model
Measure of
Association (95% CI) Significance
per 10 mL/min/1.73 m
2
Linear Regression b P Value
Model 1 0.01 (-0.09, 0.11) 0.81
Model 2 -0.01 (-0.10, 0.09) .91
Categorical Regressions Odds Ratio P Value
Ordered logistic regression 1.01 (0.91, .13) 0.85
Logistic regression 0.99 (0.87, 1.13) 0.90
Categorical models and linear Model 1 adjusted for age, sex, race, diabetes,
hypertension, smoking, cholesterol, congestive heart failure, peripheral vascular
disease, obstructive lung disease and recruitment site. Model 2 additionally
adjusted for Hispanic ethnicity and serum albumin. CI=confidence intervals.
CKD=chronic kidney disease.
doi:10.1371/journal.pone.0023718.t005
Table 6. Adjusted Association of CKD Stage with Endoglin Concentration.
Model Measure of Association (95% CI) Significance
per 10 mL/min/1.73 m
2
Linear Regression b P Value
Model 1
Preserved Renal function/Stage 1 CKD Reference Reference
Stage 2 CKD -0.04 (-0.82, 0.74) 0.93
Stage 3 CKD -0.04 (-0.89, 0.81) 0.93
Stage 4-5 CKD 0.34 (-0.73, 1.40) 0.54
Dialysis -0.08 (-1.48, 1.31) 0.91
Model 2
Preserved Renal function/Stage 1 CKD Reference Reference
Stage 2 CKD -0.00 (-0.77, 0.76) 0.99
Stage 3 CKD -0.07 (-0.91, 0.76) 0.86
Stage 4-5 CKD 0.43 (-0.63, 1.49) 0.42
Dialysis 0.39 (-0.98, 1.77) 0.57
Categorical Regressions Odds Ratio P Value
Ordered logistic regression
Preserved Renal function/Stage 1 CKD Reference Reference
Stage 2 CKD 1.05 (0.45, 2.45) 0.91
Stage 3 CKD 1.20 (0.48, 3.00) 0.70
Stage 4–5 CKD 1.28 (0.39, 4.24) 0.68
Dialysis 1.09 (0.24, 4.99) 0.92
Logistic regression
Preserved Renal function/Stage 1 CKD Reference Reference
Stage 2 CKD 0.74 (0.28, 2.00) 0.54
Stage 3 CKD 0.96 (0.33, 2.78) 0.93
Stage 4–5 CKD 0.91 (0.23, 3.55) 0.89
Dialysis 1.78 (0.30, 10.58) 0.53
Categorical models and linear Model 1 adjusted for age, sex, race, diabetes, hypertension, smoking, cholesterol, congestive heart failure, peripheral vascular disease,
obstructive lung disease and recruitment site. Model 2 additionally adjusted for Hispanic ethnicity and serum albumin. CI=confidence intervals. CKD=chronic kidney
disease.
doi:10.1371/journal.pone.0023718.t006
Endoglin in CKD
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inhibitors might occur in CKD and predispose individuals with
CKD to cardiovascular disease and preeclampsia. The present
study, however, suggests a more complex biology with disparate
associations between renal function and the various pro and anti-
angiogenic factors.
Endoglin plays an important role in embryonic heart develop-
ment [31,38] and is also involved in post-embryonic maintenance
of normal cardiovascular function. Endoglin expression on
coronary artery endothelial cells appears to modulate the effects
of angiotensin 2 on vascular remodeling [39], and it helps regulate
vascular reactivity via improved coupling of eNOS activity
[30,40]. The expression of the soluble form is negatively regulated
by heme-oxygenase-1 [41], which itself plays a key role in cellular
responses to oxidative stress and ischemia-reperfusion injury [42].
Finally, in more general terms, studies of both plaque angiogenesis
[14] and myocardial angiogenesis [12,13] have strongly implicated
angiogenesis-related factors (such as endoglin) as important players
in cardiovascular pathophysiology.
On the basis of this evidence, important effects on cardiovas-
cular homeostasis would be expected if renal injury induced
changes in circulating endoglin concentrations comparable to the
changes observed in intra-renal tissue levels. To our knowledge,
however, the hypothesis that changes in soluble endoglin
concentration partly underlie the high incidence of cardiovascular
morbidity and mortality in individuals with CKD has not been
previously investigated. The absence of significant increases in
soluble endoglin levels in the setting of CKD in the current study,
suggests that (despite the theoretical attractiveness of our initial
hypothesis) that soluble endoglin is not an important factor in the
etiology in the enhanced atherosclerosis and cardiovascular disease
that accompanies CKD.
It should be noted, that when individuals with the most severe
forms of CKD—those with ESRD—were excluded, our data was
more suggestive of a trend towards increasing endoglin concen-
tration with declining GFR. However, even within this subgroup,
the differences across categories of CKD were small and did not
achieve statistical significance. Nevertheless, additional studies
including larger numbers of individuals with both ESRD and pre-
dialysis CKD are needed to clarify the behavior of endoglin in the
most advanced stages of CKD.
Other limitations of our study should be recognized. We were
unable to measure GFR directly and thus estimated GFR on the
basis of serum creatinine level at the time of recruitment. GFR
estimating equations are susceptible to inaccuracy, and we cannot
rule out the possibility that CKD status was misclassified in some
cases. Such misclassification is unlikely to explain our findings
since we excluded patients with overt acute kidney injury,
recruited many patients from a renal clinic (in which individuals
generally have overt/well-established CKD), and because en-
doglin concentrations were lowest in the group with ESRD in
whom estimation of GFR was not needed to classify the CKD
status. Another issue is that the numbers of individuals with ESRD
and severely reduced GFR was small. Additional studies including
larger number of patients with advanced renal disease are
warranted to confirm our findings.
It should also be noted that our patients were recruited from 2
different settings within a single hospital. The single-center nature
of our study may limit the generalizability of our findings to other
populations with CKD, and our findings merit confirmation in
populations from other centers. Soluble endoglin levels collected
within a single, uniform setting within our center would likely have
been more homogenous. However, our approach has the
advantage of being generalizable to a fuller spectrum of CKD
patients and presentations than would have been possible had we
recruited patients at only a single site within the institution.
Additionally, although absolute levels were somewhat different
between the two subgroups, the relative change across categories
of CKD was similar regardless of subgroup, and our findings were
unchanged when recruitment site was included as a co-factor in
multivariable analyses.
In conclusion, soluble endoglin has been implicated in the
pathogenesis of renal and cardiovascular disease. To understand
whether increases in the concentration of soluble endoglin underlie
the strong associations of CKD with increased risks of developing
cardiovascular death, we analyzed soluble endoglin concentrations
Figure 3. Association of endoglin concentration and urinary albumin excretion. Scatter plot of endoglin concentration vs. microalbumin to
creatinine ratio
doi:10.1371/journal.pone.0023718.g003
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.in a large cohort of individuals with and without CKD and found
no association between eGFR or urinary albumin excretion and
soluble endoglin levels. Our findings suggest that increases in the
baseline levels of soluble endoglin in individuals with CKD are
unlikely to contribute to the progression of CKD or to explain
CKD-associated cardiovascular disease.
Supporting Information
Figure S1 Restricted cubic spline analysis of the association of
GFR with endoglin concentration.
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